Here is your Pro Recap of the biggest analyst picks you may have missed since yesterday: a buy initiation and upgrade at Amazon.com, as well as upgrades at Aptive, Marsh & McLennan, and Glaukos.

InvestingPro subscribers got this news before anyone else. Start your 7-day trial to get on board.

Amazon started at Overweight by Wells Fargo, upped by Edgewater

Wells Fargo initiated coverage on Amazon.com (NASDAQ:) with an Overweight rating and a price target of $159.00. Meanwhile, Edgewater Research upgraded the company to Outperform from Market Perform.

(NYSE:) cited the company's recent shift to a regional fulfillment model for deliveries, which it believes could bring shares at least 30% higher than where they are currently trading.

Yesterday, The Wall Street Journal reported that Amazon is planning to launch an ad-supported tier for its Prime Video streaming service. Additionally, Amazon is reportedly in talks with Warner Bros Discovery (NASDAQ:) and Paramount (NASDAQ:) to add ad-based tiers to their streaming services through Prime Video channels. Amazon, Paramount, and Warner have declined to comment on the matter, the WSJ said.

Aptive upgraded to Outperform

Wolfe Research upgraded Aptiv (NYSE:) to Outperform from Peerperform with a price target of $130.00.

The firm sees several upcoming catalysts for Aptive, including a strong upward trajectory for margins, and significant potential for upside to consensus estimates. 2023 Street consensus of $4.38 EPS is consistent with the company's $4.00-$4.50 guidance, but Wolfe expects guidance to be raised on Q2/23 earnings call in August.

2 more upgrades

Evercore ISI upgraded Marsh & McLennan (NYSE:) to Outperform from In Line and raised its price target to $199.00 from $195.00, expecting a 4-5% upside to consensus EPS with more visibility given a greater ability to leverage Centers of Excellence.

Piper Sandler upgraded Glaukos (NYSE:) to Overweight from Neutral and raised its price target to $80.00 from $55.00, noting it believes the Street is underestimating the ramp of both iStent Infinite and, more critically, iDose.

Jump on the biggest news for your portfolio amid a barrage of market headlines: Always be the first to know with InvestingPro.

Start your free 7-day trial now.